# US 2018/0021398 A1 · Fermented pennisetum extract

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021398 A1
- Document ID: US20180021398A1
- Status: Published application
- Kind: A1
- Application number: 15/213,806
- Filed: 2016-07-19
- Published: 2018-01-25
- Earliest claimed: 2016-07-19
- Assignees: Sagittarius Life Science Corp.
- Applicants: Sagittarius Life Science Corp.
- Inventors: Ming-Chi Shih
- Web page: https://patentgrep.com/patent/US20180021398A1

## CPC

- A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12P 1/02: by using fungi
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2236/19: involving fermentation using yeast, bacteria or both; enzymatic treatment
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The invention provides a fermented Pennisetum extract, which has an advantageous effect in treating and preventing a cancer without toxicity to normal cells. The invention also provides a process of preparing the fermented Pennisetum extract and the application of the fermented Pennisetum extract in the treatment or prevention of a cancer.

## Claims

### Claim 1

A fermented Pennisetum extract, comprising a compound ZG5236 having a chromatograph having at least a peak at retention times of 17.18 to 17.98 minutes assayed by HPLC.

### Claim 2 (depends on 1)

The extract of claim 1, wherein the peak is at retention time of about 17.53 minutes.

### Claim 3 (depends on 1)

The extract of claim 1, which further comprises a compound ZG5235 having a chromatograph having the peak at retention times of: 16.20 to 17.10 minutes, and/or a compound ZG5237 having a chromatograph having the peak at retention times of: 19.00 to 19.36 minutes.

### Claim 4 (depends on 3)

The extract of claim 3, wherein the peak of ZG5235 is at a retention time of about 16.63 minutes and the peak of ZG5237 is at a retention time of about 19.18 minutes.

### Claim 5 (depends on 3)

The extract of claim 3, wherein ZG5236 accounts for 5.88% of the extract. In another embodiment, the amounts of ZG5235 and ZG5237 account for 1.47% and 0.13%, respectively

### Claim 6 (depends on 1)

The extract of claim 1, which is prepared by the process comprising the following steps: (a) culturing Pennisetum solution with Aspergillus niger for a biotransformation; (b) collecting the solution and then extracting an extract with an organic solvent; and (c) analyzing the extract by High Performance Liquid Chromatography (HPLC) at 330 nm.

### Claim 7 (depends on 6)

The extract of claim 6, wherein the amount of ZG5236 after biotransformation increases about 20.99% in comparison with that before biotransformation, or the amounts of ZG5235 and ZG5237 after biotransformation reduce about 8.8% and about 1.39%, respectively.

### Claim 8 (depends on 1)

The extract of claim 1, wherein the Pennisetum is selected from the group consisting of: Pennisetum alopecuroides (L.), Pennisetum clandestinum, Pennisetum polystachion (L.), Pennisetum purpureum and Pennisetum setosum.

### Claim 9 (depends on 6)

The extract of claim 6, wherein the Pennisetum is Pennisetum alopecuroides (L.) or Pennisetum purpureum.

### Claim 10 (depends on 6)

The extract of claim 6, wherein the organic solvent of step (b) is an alcohol.

### Claim 11 (depends on 10)

The extract of claim 10, wherein the alcohol is methanol, ethanol, propanol or isopropanol.

### Claim 12 (depends on 6)

The extract of claim 6, wherein after step (b), the process comprises a further step (b1) of concentrating the extract to a concentrated extract.

### Claim 13 (depends on 6)

The extract of claim 6, wherein the HPLC is carried out under the following condition: the mobile phase is 0.5 mM ammonium acetate solution with formic acid adjusted pH to 3.5 (solvent A)-methanol (solvent B) in the following gradient:
Time
Solvent (A)
Solvent (B)
0
70
30
12
60
40
17
50
50
22
60
40
26
65
35
30
70
30

### Claim 14

A process for preparing a fermented Pennisetum extract, comprising the following steps: (a) culturing Pennisetum solution with Aspergillus niger for a biotransformation; (b) collecting the resulting cultured solution and then extracting the solution with an organic solvent to obtain an extract; and (c) analyzing the extract by High Performance Liquid Chromatography (HPLC) at 254 nm and 330 nm.

### Claim 15 (depends on 1)

A composition comprising an amount of the Pennisetum extract of claim 1.

### Claim 16 (depends on 15)

The composition of claim 15, which comprises a second anti-cancer agent.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the second anti-cancer agent is an alkylating agent, an antimetabolite, an anti-microtubule agent, a topoisomerase inhibitor or a cytotoxic antibiotic.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the second anti-cancer agent is an alkylating agent, an antimetabolite, an anti-microtubule agent, a topoisomerase inhibitor or a cytotoxic antibiotic.

### Claim 19 (depends on 16)

The composition of claim 16, which is a pharmaceutical composition, dietary supplement composition, a supplementary composition for a patient receiving chemotherapy, a health food composition or a food composition.

### Claim 20 (depends on 16)

The composition of claim 16, which is in the form of solution, suspension, emulsion, powder, pill, tablet or capsule.

### Claim 21 (depends on 1)

A method for treating a cancer and/or invasion and metastasis of cancer in a subject in need thereof, comprising administering to the subject an effective amount of the Pennisetum extract of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the effective amount ranges from 2 mg/kg to 20 mg/kg.

### Claim 23 (depends on 22)

The method of claim 22, wherein the cancer is lung cancer, squamous cell carcinomas of the lung, head and neck, breast cancer, ovarian cancer, prostate cancer, gastric carcinoma, cervical cancer, esophageal carcinoma, bladder cancer, brain cancer, liver cancer, or colon cancer.

### Claim 24 (depends on 22)

The method of claim 22, wherein the cancer is lung cancer.

### Claim 25 (depends on 24)

The method of claim 24, wherein the lung cancer is small cell lung cancer or non-small cell lung cancer.

### Claim 26 (depends on 21)

The method of claim 21, wherein the Pennisetum extract is administered in combination with radiotherapy and chemotherapy.

### Claim 27 (depends on 21)

The method of claim 21, which comprises further administering a second anti-cancer agent.

### Claim 28 (depends on 27)

The method of claim 27, wherein the Pennisetum extract and the second anti-cancer agent are administered simultaneously, sequentially or separately.

### Claim 29 (depends on 27)

The method of claim 27, wherein the second anti-cancer agent is an alkylating agent, an antimetabolite, an anti-microtubule agent, a topoisomerase inhibitor or a cytotoxic antibiotic.

### Claim 30 (depends on 27)

The method of claim 27, wherein the second anti-cancer agent is cisplatin, taxol, docetaxel, vinorelbine, vindesine, vinflunine, gemcitabine, methotrexate, gefitinib, lapatinib or erlotinib.
